- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT05789082
En studie som evaluerer sikkerheten, aktiviteten og farmakokinetikken til GDC-6036 i kombinasjon med andre anti-kreftterapier hos deltakere med tidligere ubehandlet avansert eller metastatisk ikke-småcellet lungekreft med en KRAS G12C-mutasjon (KRAScendo 170)
En fase Ib/II, åpen, multisenterstudie som evaluerer sikkerheten, aktiviteten og farmakokinetikken til GDC-6036 i kombinasjon med andre anti-kreftterapier hos pasienter med tidligere ubehandlet avansert eller metastatisk ikke-småcellet lungekreft med en KRAS G12C Mutasjon
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and activity of single-agent divarasib or combined with other anti-cancer therapies in participants with previously untreated, advanced or metastatic non-small cell lung cancer (NSCLC).
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering (Antatt)
Fase
- Fase 2
- Fase 1
Kontakter og plasseringer
Studiekontakt
- Navn: Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry
Studer Kontakt Backup
- Navn: Reference Study ID Number: BO44426 https://forpatients.roche.com/ No attachments to email below.
- Telefonnummer: 888-662-6728 (U.S. and Canada)
- E-post: global-roche-genentech-trials@gene.com
Studiesteder
-
-
-
Buenos Aires, Argentina, C1280AEB
- Rekruttering
- Hospital Britanico
-
Ciudad Autonoma Buenos Aires, Argentina, C1430EGF
- Rekruttering
- Clinica Adventista Belgrano
-
La Rioja, Argentina, F5300COE
- Rekruttering
- Centro Oncologico Riojano Integral (CORI)
-
-
-
-
New South Wales
-
Concord, New South Wales, Australia, 2139
- Fullført
- Concord Repatriation General Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Rekruttering
- Peter MacCallum Cancer Centre
-
Melbourne, Victoria, Australia, 3004
- Rekruttering
- Alfred Health
-
-
-
-
-
Brussels, Belgia, 1200
- Rekruttering
- Cliniques Universitaires St-Luc
-
Hasselt, Belgia, 3500
- Rekruttering
- Jessa Zkh (Campus Virga Jesse)
-
Namur, Belgia, 5000
- Rekruttering
- Clinique Ste-Elisabeth
-
Roeselare, Belgia, 8800
- Rekruttering
- AZ Delta (Campus Rumbeke)
-
-
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Rekruttering
- Hospital de Cancer de Barretos
-
São Paulo, São Paulo, Brasil, 01246-000
- Rekruttering
- Instituto do Cancer do Estado de Sao Paulo - ICESP
-
-
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8M2
- Rekruttering
- Ottawa Hospital Regional Cancer Centre
-
Toronto, Ontario, Canada, M5G 1Z5
- Aktiv, ikke rekrutterende
- Princess Margaret Cancer Center
-
-
Quebec
-
Montreal, Quebec, Canada, H3T 1E2
- Rekruttering
- Jewish General Hospital
-
-
-
-
California
-
Duarte, California, Forente stater, 91010
- Tilbaketrukket
- City of Hope National Medical Center
-
Huntington Beach, California, Forente stater, 92648
- Tilbaketrukket
- City of Hope - Seacliff
-
Irvine, California, Forente stater, 92618
- Tilbaketrukket
- City of Hope at Irvine Lennar
-
La Jolla, California, Forente stater, 92093
- Tilbaketrukket
- UCSD Moores Cancer Center
-
Long Beach, California, Forente stater, 90813
- Tilbaketrukket
- City of Hope - Long Beach Elm
-
-
Connecticut
-
New Haven, Connecticut, Forente stater, 06520
- Rekruttering
- Yale Cancer Center
-
-
Florida
-
Fort Myers, Florida, Forente stater, 33901-8108
- Rekruttering
- Florida Cancer Specialists - SOUTH - SCRI - PPDS
-
St. Petersburg, Florida, Forente stater, 33705-1400
- Rekruttering
- Florida Cancer Specialists - NORTH - SCRI - PPDS
-
West Palm Beach, Florida, Forente stater, 33401-3406
- Rekruttering
- Florida Cancer Specialists - EAST - SCRI - PPDS
-
-
New York
-
Mineola, New York, Forente stater, 11501
- Rekruttering
- NYU Langone Hospital - Long Island
-
New York, New York, Forente stater, 10016
- Rekruttering
- NYU Cancer Center
-
New York, New York, Forente stater, 10029
- Rekruttering
- Mount SInai Medical Center
-
The Bronx, New York, Forente stater, 10461
- Rekruttering
- Montefiore Medical Center - Montefiore Medical Park
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- MD Anderson Cancer Center
-
-
Virginia
-
Blacksburg, Virginia, Forente stater, 24060
- Rekruttering
- Oncology & Hematology Associates of Southwest Virginia, Inc
-
Norfolk, Virginia, Forente stater, 23502
- Rekruttering
- Virginia Oncology Associates
-
-
-
-
-
Haifa, Israel, 3109601
- Rekruttering
- Rambam Medical Center
-
Petah Tikva, Israel, 4941492
- Rekruttering
- Rabin MC
-
Tel Aviv, Israel, 6423906
- Rekruttering
- Tel Aviv Sourasky Medical Ctr
-
-
-
-
Campania
-
Naples, Campania, Italia, 80131
- Tilbaketrukket
- Istituto Nazionale Tumori Fondazione G. Pascale
-
-
Lazio
-
Rome, Lazio, Italia, 00168
- Aktiv, ikke rekrutterende
- Policlinico Universitario Agostino Gemelli IRCCS
-
-
Lombardy
-
Milan, Lombardy, Italia, 20133
- Rekruttering
- Irccs Istituto Nazionale Dei Tumori (Int)
-
-
Piedmont
-
Orbassano, Piedmont, Italia, 10043
- Rekruttering
- A.O. Universitaria S. Luigi Gonzaga
-
-
-
-
-
Chiba, Japan, 277-8577
- Rekruttering
- National Cancer Center Hospital East
-
Osaka, Japan, 589-8511
- Rekruttering
- Kindai University Hospital
-
Tokyo, Japan, 104-0045
- Fullført
- National Cancer Center Hospital
-
Tokyo, Japan, 135-8550
- Tilbaketrukket
- The Cancer Institute Hospital of JFCR
-
Wakayama, Japan, 641-8510
- Tilbaketrukket
- Wakayama Medical University Hospital
-
-
-
-
-
Changsha, Kina, 410013
- Rekruttering
- Hunan Cancer Hospital
-
Harbin, Kina, 150081
- Rekruttering
- Harbin Medical University Cancer Hospital
-
Shanghai, Kina, 200433
- Rekruttering
- Shanghai Pulmonary Hospital
-
-
-
-
-
Amsterdam, Nederland, 1066 CX
- Aktiv, ikke rekrutterende
- NKI The Netherlands Cancer Institute
-
Nijmegen, Nederland, 6525 GA
- Rekruttering
- UMC St Radboud
-
-
-
-
-
Gda?sk, Polen, 80-214
- Rekruttering
- Uniwersyteckie Centrum Kliniczne
-
Krakow, Polen, 31-202
- Rekruttering
- Krakowski Szpital Specjalistyczny im sw. Jana Paw?a II
-
Olsztyn, Polen, 10-357
- Rekruttering
- Warminsko-Mazurskie Centrum Chorób P?uc w Olsztynie
-
-
-
-
-
Barcelona, Spania, 08035
- Rekruttering
- Vall d?Hebron Institute of Oncology (VHIO), Barcelona
-
Madrid, Spania, 28041
- Rekruttering
- Hospital Universitario 12 de Octubre
-
Madrid, Spania, 28007
- Rekruttering
- Hospital General Universitario Gregorio Marañon
-
Seville, Spania, 41013
- Rekruttering
- Hospital Universitario Virgen del Rocio
-
Valencia, Spania, 46010
- Rekruttering
- Hospital Clinico Universitario de Valencia
-
-
Barcelona
-
Badalona, Barcelona, Spania, 08916
- Rekruttering
- ICO Badalona-H.U. Germans Trias i Pujol
-
-
-
-
-
Glasgow, Storbritannia, G12 0YN
- Rekruttering
- Beatson West of Scotland Cancer Centre
-
London, Storbritannia, EC1A 7BE
- Rekruttering
- Barts & London School of Med
-
-
-
-
-
Basel, Sveits, 4031
- Rekruttering
- Universitätsspital Basel
-
Bern, Sveits, 3010
- Tilbaketrukket
- Inselspital Bern
-
-
-
-
-
Gothenburg, Sverige, 411 36
- Rekruttering
- Sahlgrenska University Hospital
-
-
-
-
-
Busan, Sør -Korea, 49241
- Rekruttering
- Pusan National University Hospital
-
Seoul, Sør -Korea, 05505
- Rekruttering
- Asan Medical Center
-
Seoul, Sør -Korea, 03080
- Rekruttering
- Seoul National University Hospital
-
Seoul, Sør -Korea, 06351
- Rekruttering
- Samsung Medical Center
-
Seoul, Sør -Korea, 08308
- Rekruttering
- Korea University Guro Hospital
-
-
-
-
-
Taichung, Taiwan, 407
- Rekruttering
- Taichung Veterans General Hospital
-
Tainan, Taiwan
- Rekruttering
- National Cheng Kung University Hospital
-
Taipei, Taiwan, 100
- Rekruttering
- National Taiwan Uni Hospital
-
Taoyuan, Taiwan, 333
- Rekruttering
- Chang Gung Medical Foundation - Linkou
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Confirmation of Biomarker eligibility
- Pre-treatment tumor tissue along with an associated pathology report is required for all participants enrolled on study. Representative tumor specimens must be in formalin-fixed, paraffin embedded (FFPE) blocks (preferred) or 15 unstained, freshly cut, serial slides. Although 15 slides are required, if only 10 slides are available, the participant may be eligible for the study following consultation with the Sponsor.
- Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1
- Histologically or cytologically documented locally advanced unresectable or metastatic NSCLC that is not eligible for curative surgery and/or definitive chemoradiotherapy
- No prior systemic treatment for advanced unresectable or metastatic NSCLC
- Measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Additionally, for participants in cohort D, measurable brain metastases defined as at least 5 millimeters and twice the slice thickness, but less than 20 mm, that is asymptomatic and does not require local therapy at the time of enrollment.
Exclusion Criteria:
- Known concomitant second oncogenic driver with available targeted treatment
- Squamous cell histology NSCLC
- Symptomatic, untreated, or actively progressing CNS metastases (Cohorts A, B, and C)
- Prior treatment with a KRAS G12C inhibitor
- Known hypersensitivity to any of the components of divarasib or pembrolizumab; or known hypersensitivity to pemetrexed, carboplatin, or cisplatin (Cohort B only)
- History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis, active tuberculosis, significant cardiovascular disease within 3 months prior to initiation of study treatment
- History of malignancy other than NSCLC within 5 years prior to initiation of study treatment, with the exception of malignancies with a negligible risk of metastasis or death (e.g., 5-year OS rate more >90%), such as adequately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, localized prostate cancer, ductal breast carcinoma in situ, or Stage I uterine cancer
- Uncontrolled tumor related pain, pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures, uncontrolled or symptomatic hypercalcemia
- Co-morbid condition that is an absolute contraindication to treatment with corticosteroids
- Inability or unwillingness to take prophylactic treatments such as corticosteroids, anti-emetics, folic acid, or vitamin B12 supplementation.
- Participants with brain metastases for whom complete surgical resections is clinically appropriate
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Cohort A - Combination Dose Finding + Dose Expansion
Participants will be enrolled in different cohorts to receive divarasib (different dose levels will be evaluated) once a day (QD) combined with pembrolizumab 200 mg intravenous (IV) infusion every 3 weeks (Q3W). During the expansion stage, some participants are planned to be randomized to one divarasib combination dose level; other participants are planned to be randomized to another divarasib combination dose level. Divarasib will be given in combination with pembrolizumab. |
Participants will receive divarasib orally (PO), QD on days 1-21 of each 21-day cycle. Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle. |
|
Eksperimentell: Cohort B - Combination Dose Finding + Dose Expansion
Participants enrolled in this cohort will receive divarasib (different dose levels will be evaluated) QD combined with pembrolizumab 200 mg IV Q3W plus investigator's choice of platinum-based chemotherapy (carboplatin or cisplatin) and pemetrexed. |
Participants will receive divarasib orally (PO), QD on days 1-21 of each 21-day cycle. Participants will receive a 200 mg IV infusion of pembrolizumab Q3W on Day 1 of each 21-day cycle. Participants will receive IV carboplatin Q3W for four 21-day cycles. Participants will receive IV cisplatin Q3W for four 21-day cycles. Participants will receive IV pemetrexed Q3W. |
|
Eksperimentell: Cohort C - Dose Expansion
Participants enrolled in this cohort will receive one dose level of divarasib QD. |
Participants will receive divarasib orally (PO), QD on days 1-21 of each 21-day cycle. |
|
Eksperimentell: Cohort D - Dose Expansion
Participants enrolled in this cohort will receive one dose level of divarasib QD. |
Participants will receive divarasib orally (PO), QD on days 1-21 of each 21-day cycle. |
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Prosentandel av deltakerne med bivirkninger (AES)
Tidsramme: Baseline inntil 60 dager etter den endelige dosen av studiebehandling eller til initiering av en annen antikreftterapi, avhengig av hva som skjer først (opptil omtrent 5 år)
|
Baseline inntil 60 dager etter den endelige dosen av studiebehandling eller til initiering av en annen antikreftterapi, avhengig av hva som skjer først (opptil omtrent 5 år)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Endring fra baseline i symptomatiske bivirkninger, som vurdert ved bruk av pro-CTCAE
Tidsramme: Baseline opp til omtrent 5 år
|
Baseline opp til omtrent 5 år
|
|
|
Antall deltakere som rapporterer forekomst, hyppighet, alvorlighetsgrad og/eller grad av innblanding i daglig funksjon av symptomatiske bivirkninger som vurdert gjennom Patient-Reported Outcomes Common Terminology Criteria for Adverse Events (PRO-CTCAE)
Tidsramme: Omtrent 5 år
|
Omtrent 5 år
|
|
|
Prosentandel av deltakere som rapporterte "Hyppig" eller "Nesten konstant" diaré i løpet av de tre første behandlingssyklusene i henhold til PRO-CTCAE-kriteriene
Tidsramme: Omtrent 5 år
|
Omtrent 5 år
|
|
|
Prosentandel av deltakere som rapporterte "alvorlig" eller "svært alvorlig" kvalme eller oppkast under de tre første behandlingssyklusene i henhold til PRO-CTCAE
Tidsramme: Omtrent 5 år
|
Omtrent 5 år
|
|
|
Frekvens av deltakers vurdering av graden de er plaget med behandlingssymptomer, vurdert gjennom bruk av European Organisation for Research and Treatment of Cancer (EORTC) Item List 46 (IL46) med ett enkelt spørsmål
Tidsramme: Omtrent 5 år
|
Omtrent 5 år
|
|
|
Objective Response Rate (ORR)
Tidsramme: Approximately 5 years
|
The percentage of participants who experience a complete response or partial response, as determined by the investigator, according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 |
Approximately 5 years
|
|
Duration of Response (DOR)
Tidsramme: Approximately 5 years
|
The time from the first occurrence of a documented objective response to disease progression or death from any cause (whichever occurs first), as determined by the investigator according to RECIST v1.1 |
Approximately 5 years
|
|
Progression Free Survival (PFS)
Tidsramme: Approximately 5 years
|
The time from randomization, or date of first treatment for participants enrolled prior to the expansion stage, to the first occurrence of disease progression or death from any cause during the study (whichever occurs first), as determined by the investigator according to RECIST v1.1 |
Approximately 5 years
|
|
Plasma or CSF Concentration of Divarasib at Specified Timepoints
Tidsramme: Approximately 5 years
|
Optional CSF samples may be collected at the time of disease progression or at any time during the study for participants who have provided written consent and if collection of CSF sample is deemed clinically feasible. Matched optional plasma samples may be drawn at the same time. |
Approximately 5 years
|
|
Identification of Divarasib Recommended Dose
Tidsramme: Approximately 5 years
|
The recommended dose will be based upon the totality of safety, activity, and PK data. |
Approximately 5 years
|
|
Central Nervous System (CNS) Response
Tidsramme: Approximately 5 years
|
Defined as the percentage of participants who experience a complete response or partial response in the brain, as determined by the investigator according to modified RECIST |
Approximately 5 years
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Studieleder: Clinical Trials, Hoffmann-La Roche
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
- Neoplasmer etter nettsted
- Neoplasmer
- Sykdommer i luftveiene
- Lungesykdommer
- Neoplasmer i luftveiene
- Thoracale neoplasmer
- Lungeneoplasmer
- Karsinom, bronkogent
- Bronkiale neoplasmer
- Karsinom, ikke-småcellet lunge
- Aminosyrer, peptider og proteiner
- Organiske kjemikalier
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Uorganiske kjemikalier
- Klorforbindelser
- Nitrogenforbindelser
- Koordinasjonskomplekser
- Guanin
- Hypoksantiner
- Purinoner
- Puriner
- Glutamater
- Aminosyrer, sure
- Aminosyrer
- Aminosyrer, dikarboksyl
- Platinumforbindelser
- Pemetrexed
- Karboplatin
- Cisplatin
- pembrolizumab
Andre studie-ID-numre
- BO44426
- 2022-003048-28 (EudraCT-nummer)
- 2023 (U.S. NIH-stipend/kontrakt)
- 2023-507171-22-00 (Ctis)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .